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Introduction
Myositis specific autoantibodies (MSA), exclusively found
in patients with Idiopathic Inflammatory Myopathies can
be detected in approximately 60% of children with JDM.
Anti-MDA5 antibodies, a subgroup of MSA, appear to be
associated with clinically amyopathic myositis, rapidly
progressive interstitial lung disease (RP-ILD) and a poor
prognosis in adult East Asian dermatomyositis patients.
Small studies in Japanese children with JDM have sug-
gested similar disease phenotype. This contrasts dramati-
cally with findings in predominantly Caucasian US adult
populations where anti-MDA5 has been associated with
a distinct cutaneous phenotype and no association with
RP-ILD has been found.
Objectives
We aimed to determine the frequency and associated clin-
ical phenotype of anti-MDA5 autoantibodies in a large UK
based, predominantly Caucasian, cohort of patients with
JDM.
Methods
Serum samples, from 285 patients with JDM were
obtained through JDM National (UK and Ireland) Cohort
and Biomarker Study and Repository for Idiopathic
Inflammatory Myopathies. The presence of anti-MDA5
antibodies was determined by ELISA using recombinant
MDA5 protein. Results were compared with matched
clinical data, muscle biopsies (scored by a single experi-
enced paediatric neuropathologist) and chest imaging
(reviewed by a single experienced paediatric radiologist).
Both biopsy scoring and imaging review were performed
blind to clinical or serological data.
Results
Anti-MDA5 antibodies were identified in 7.4% of JDM
patients and were associated with a distinct clinical pheno-
type including skin ulceration (p = 0.025), oral ulceration
(p = 0.013), arthritis (p = 0.002) and milder muscle disease
both clinically (as determined by a higher lowest ever
Childhood Myositis Activity Score (p = 0.024)) and histo-
logically (as determined by a lower JDM muscle biopsy
score). Five out of 14 children had radiological evidence of
interstitial lung disease (ILD) but none had RP-ILD.
Despite these associations children with anti-MDA5 had
an improved prognosis and a greater proportion achieved
disease remission at 2 years post diagnosis according to
PRINTO criteria (p = 0.023).
Conclusion
Anti-MDA5 antibodies can be identified in a small but sig-
nificant proportion of UK children with JDM. They iden-
tify a distinctive subgroup with an increased risk of skin
and oral ulceration, arthritis, ILD and milder muscle dis-
ease, both clinically and histologically. Screening for anti-
MDA5 autoantibodies at diagnosis would be useful to
guide further investigation for possible lung disease,
inform on prognosis and potentially to confirm the diag-
nosis, as subtle biopsy changes could otherwise be missed.
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